Latest Asx News

The ASX has suspended trading of Olympio Metals and Thorney Technologies shares due to delayed periodic report filings, highlighting ongoing compliance challenges for both companies.

Westgold Resources is set to demerge its non-core Reedy and Comet gold projects into a new ASX-listed entity, Valiant Gold, aiming to unlock value and fast-track cash flow through a strategic ore purchase agreement.

Diatreme Resources has submitted the Draft Environmental Impact Statement for its Northern Silica Project, marking a significant step toward regulatory approval and highlighting its potential to boost regional economies and support global solar energy growth.

Resolution Minerals appoints Dr Adam Roper as Chief Metallurgist to advance antimony, tungsten, and gold processing at its Idaho Horse Heaven Project, aligning with US defense supply chain goals.

Fortuna Metals has confirmed a significant rutile discovery at its Mkanda project in Malawi, with high-grade drill results reaching up to 2.21% rutile over wide intervals. This discovery, adjacent to a world-class deposit, signals strong potential for a large-scale titanium feedstock resource.

Biotron Limited’s BITO securities have been suspended from ASX trading due to non-compliance with key listing rules, raising questions about the company’s next steps.

Mt Malcolm Mines has executed a binding agreement to acquire key components of a 500,000 tonnes per annum gold processing plant, positioning itself for future self-processing and toll-milling opportunities in the prolific Leonora gold region.

EV Resources is set to begin a fully funded maiden diamond drilling program at its high-grade Los Lirios antimony project in Mexico, aiming to define a maiden JORC resource by Q3 2026. This marks a pivotal step toward production readiness and a broader 2026 exploration campaign.

Prescient Therapeutics has secured European authorization to initiate a Phase 2a clinical trial of its novel cancer drug PTX-100 for relapsed/refractory Cutaneous T-cell Lymphoma, enabling trial site activation in Italy.

Cynata Therapeutics has finalised patient enrolment in its pivotal Phase 2 trial of CYP-001 for acute graft versus host disease, setting the stage for critical data due mid-2026.

Nova Minerals Limited has voluntarily suspended trading of its shares on the ASX pending a capital raising announcement expected on 17 December 2025.

Neuren Pharmaceuticals’ partner Acadia secures FDA approval for DAYBUE STIX, a new powder formulation of trofinetide offering greater flexibility for Rett syndrome patients. This milestone expands treatment options and sets the stage for increased royalty revenue in 2026.